TRCT
ZVSA

Tower Research Capital (TRC)’s ZyVersa Therapeutics ZVSA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,525
Closed -$3.06K – 5690
2025
Q2 		$3.06K Buy
4,525
+2,370
+110% +$1.55K ﹤0.01% 4556
2025
Q1 		$1.35K Sell
2,155
-1,328
-38% -$1.5K ﹤0.01% 4728
2024
Q4 		$3.69K Buy
3,483
+917
+36% +$1.45K ﹤0.01% 4614
2024
Q3 		$6.16K Buy
2,566
+1,867
+267% +$5.99K ﹤0.01% 4174
2024
Q2 		$2.63K Sell
699
-155
-18% -$831 ﹤0.01% 4981
2024
Q1 		$6.41K Buy
854
+456
+115% +$3.44K ﹤0.01% 4376
2023
Q4 		$3.58K Buy
398
+382
+2,388% +$10.7K ﹤0.01% 5058
2023
Q3 		$750 Hold
16
– – ﹤0.01% 5482
2023
Q2 		$1.41K Buy
16
+3
+23% +$787 ﹤0.01% 5381
2023
Q1 		$9K Buy
+13
New +$9.72K ﹤0.01% 4554

Other funds holding ZVSA

GA
Guerra Advisors Miami, Florida $271M AUM 27.78% 1-Year Est. Return

Tower Research Capital (TRC)'s ZVSA Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of ZyVersa Therapeutics (ZVSA) in Q3 2025, closing a stake of 4,525 shares — an estimated $3.06K sold.

Tower Research Capital (TRC) first reported a position in ZVSA in Q1 2023 and held it in 10 quarters. The position peaked at $9K in Q1 2023. 1 fund tracked by Wall St. Rank holds ZVSA as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining ZyVersa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,525 ZyVersa Therapeutics shares in Q3 2025, an estimated $3.06K.
  • Tower Research Capital (TRC) first reported a position in ZyVersa Therapeutics in Q1 2023 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s ZyVersa Therapeutics position peaked at $9K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.